Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

GeoVax Labs Inc. GOVX

Healthcare  —  Biotechnology
0.35 (0.01) (2.78%) as of 25 Sep
Market cap
$3.7M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

GeoVax Labs Inc. (GOVX) Business Profile

Updated before January 2025

Company Overview

GeoVax Labs Inc. (NASDAQ: GOVX) is a clinical-stage biotechnology company headquartered in Smyrna, Georgia, USA. Founded in 2001, the company specializes in the development of human vaccines and immunotherapies using its proprietary Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) platform technology. GeoVax’s mission is to address unmet medical needs in infectious diseases, cancer, and emerging global health threats. The company is led by a team of seasoned professionals, including David A. Dodd, Chairman and CEO, who brings decades of experience in the pharmaceutical and biotechnology industries. Other key members of the leadership team include Mark W. Reynolds, Chief Financial Officer, and Farshad Guirakhoo, Ph.D., Chief Scientific Officer.

Core Business Segments

GeoVax operates primarily in the biotechnology and pharmaceutical sectors, focusing on the following core business segments:

1. Infectious Disease Vaccines

GeoVax is actively developing vaccines for a range of infectious diseases, including:

  • HIV/AIDS: The company has developed preventive and therapeutic vaccine candidates for HIV, leveraging its MVA-VLP platform.
  • COVID-19: GeoVax is working on next-generation COVID-19 vaccines aimed at addressing emerging variants.
  • Zika Virus: The company is developing a vaccine candidate to combat the Zika virus.
  • Hemorrhagic Fevers: This includes vaccines for diseases like Ebola and Lassa fever.

2. Cancer Immunotherapies

GeoVax is expanding its portfolio to include immunotherapies for cancer. The company is exploring the use of its MVA-VLP platform to develop therapeutic vaccines targeting various types of cancer, including solid tumors and hematologic malignancies.

3. Emerging Global Health Threats

GeoVax is committed to addressing emerging global health threats by developing vaccines for diseases that pose significant public health challenges. This includes efforts to combat diseases like malaria and other neglected tropical diseases.

Business Model

GeoVax’s business model is centered around the development, clinical testing, and commercialization of vaccines and immunotherapies. The company generates revenue through:

  • Collaborations and Partnerships: GeoVax collaborates with government agencies, non-profit organizations, and pharmaceutical companies to fund and advance its vaccine candidates.
  • Licensing Agreements: The company licenses its proprietary MVA-VLP technology to other organizations for the development of vaccines and therapeutics.
  • Grants and Contracts: GeoVax secures funding from government agencies and non-governmental organizations to support its research and development efforts.

Strategic Direction

GeoVax is focused on achieving the following strategic objectives:

  • Pipeline Expansion: The company aims to expand its pipeline of vaccine candidates to address a broader range of infectious diseases and cancers.
  • Regulatory Approvals: GeoVax is working to advance its vaccine candidates through clinical trials and secure regulatory approvals for commercialization.
  • Global Partnerships: The company seeks to establish strategic partnerships with global organizations to accelerate the development and distribution of its vaccines.
  • Sustainability Goals: GeoVax is committed to sustainable practices in its research, development, and manufacturing processes.

Competitive Landscape

GeoVax operates in a highly competitive biotechnology and pharmaceutical industry. Key competitors include:

  • Moderna, Inc.: Known for its mRNA-based vaccines, including the COVID-19 vaccine.
  • Pfizer Inc.: A global leader in vaccine development and commercialization.
  • BioNTech SE: Specializes in mRNA technology for vaccines and immunotherapies.
  • Inovio Pharmaceuticals, Inc.: Focuses on DNA-based vaccines and immunotherapies.
  • Novavax, Inc.: Develops protein-based vaccines for infectious diseases.

Risk Factors

GeoVax faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: The company is subject to stringent regulatory requirements for the development and approval of its vaccine candidates.
  • Market Dependence: GeoVax’s success is heavily dependent on the commercial success of its vaccine candidates.
  • Supply Chain Disruptions: The company relies on a global supply chain for the production of its vaccines, which could be disrupted by geopolitical events or natural disasters.
  • Competition: Intense competition in the biotechnology and pharmaceutical industries could impact GeoVax’s market share.
  • Funding Risks: The company relies on external funding sources, such as grants and partnerships, to support its research and development efforts.

Recent Developments

GeoVax has made significant progress in recent years, including:

  • COVID-19 Vaccine Development: The company is advancing its COVID-19 vaccine candidates to address emerging variants.
  • Partnerships: GeoVax has entered into collaborations with organizations like the National Institutes of Health (NIH) and the Coalition for Epidemic Preparedness Innovations (CEPI).
  • Clinical Trials: The company has initiated clinical trials for several of its vaccine candidates, including those for HIV and hemorrhagic fevers.
  • Technological Innovations: GeoVax continues to enhance its MVA-VLP platform to improve the efficacy and safety of its vaccines.

Investment Considerations

Investors considering GeoVax should weigh the following strengths and risks:

Strengths

  • Innovative Technology: GeoVax’s proprietary MVA-VLP platform offers a competitive advantage in vaccine development.
  • Diverse Pipeline: The company has a robust pipeline of vaccine candidates targeting infectious diseases and cancer.
  • Strategic Partnerships: Collaborations with global organizations provide funding and accelerate development efforts.

Risks

  • Early-Stage Company: As a clinical-stage company, GeoVax has yet to commercialize its products, which poses financial risks.
  • Regulatory Hurdles: The approval process for vaccines is lengthy and uncertain.
  • Market Competition: GeoVax faces competition from well-established companies with greater resources.

Conclusion

GeoVax Labs Inc. is a promising player in the biotechnology industry, leveraging its innovative MVA-VLP platform to develop vaccines and immunotherapies for infectious diseases and cancer. While the company faces significant risks, its diverse pipeline, strategic partnerships, and commitment to addressing global health challenges position it for long-term growth. Investors should carefully consider the company’s strengths and risks before making investment decisions.